A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis
- Conditions
- Moderately to severely active rheumatoid arthritisMedDRA version: 16.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
- Registration Number
- EUCTR2012-002339-27-HU
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 660
•are at least 18 years of age
•have a diagnosis of adult-onset RA as defined by the ACR/EULAR 2010 Criteria for the Classification of RA
•have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints
•have a C-reactive protein (or hsCRP) measurement =1.2 times the upper limit of normal (ULN)
•have had an insufficient response or are intolerant to cDMARDs and either:
- have had regular use of a cDMARD for at least the 12 weeks prior to study entry with a continuous, nonchanging dose for at least 8 weeks prior to study entry
- For patients not receiving a cDMARD at the time of entry, the investigator will document in the patient’s history that the patient had failed, was unable to tolerate, or had a contraindication to treatment with a cDMARD.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
•are currently receiving corticosteroids at doses >10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization
•have started treatment with NSAIDs or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization
•are currently receiving concomitant treatment with MTX, hydroxychloroquine, and sulfasalazine or combination of any 3 cDMARDs
•have ever received any biologic DMARD
•have received interferon therapy within 4 weeks prior to study entry or are anticipated to require interferon therapy during the study
•have received any parenteral corticosteroid administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study
•have had 3 or more joints injected with intraarticular corticosteroids or hyaluronic acid within 2 weeks prior to study entry or within 6 weeks prior to planned randomization
•have active fibromyalgia that, in the investigator’s opinion, would make it difficult to appropriately assess RA activity for the purposes of this study
•have a diagnosis of any systemic inflammatory condition other than RA, such as, but not limited to juvenile chronic arthritis, spondyloarthropathy, Crohn’s disease, ulcerative colitis, psoriatic arthritis, or active vasculitis or gout
oPatients with secondary Sjogren’s syndrome are not excluded.
•have a diagnosis of Felty’s syndrome
•have had any major surgery within 8 weeks of study entry or will require major surgery during the study that, in the opinion of the investigator in consultation with Lilly or its designee, would pose an unacceptable risk to the patient
•have experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or have New York Heart Association stage IV heart failure
•have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data
•are largely or wholly incapacitated permitting little or no self care, such as, being bedridden or confined to a wheelchair
•have an eGFR based on the most recent available serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of <40 mL/min/1.73 m2
•have a history of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the ULN or the most recent available total bilirubin ?1.5 times the ULN
•have, or have a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for <5 years
•have been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)
•
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Determine whether baricitinib 4 mg QD is superior to placebo in the treatment of patients with moderately to severely active RA who have had inadequate response to or are intolerant to at least 1 cDMARD (cDMARD-IR [inadequate response] patients) and who have not received a biologic DMARD, as assessed by the proportion of patients achieving ACR20 at Week 12.;Secondary Objective: - change from baseline to Week 12 in Health Assessment Questionnaire-Disability Index (HAQ-DI) score<br>- change from baseline to Week 12 in DAS28-high-sensitivity C-reactive protein (hsCRP)<br>- proportion of patients achieving an SDAI score =3.3 at week 12<br>- proportion of patients achieving ACR20 at Week 12 (baricitinib 2mg compared to placebo);Primary end point(s): Proportion of patients achieving ACR20 response (baricitinib 4mg compared to placebo): ;Timepoint(s) of evaluation of this end point: Week 12
- Secondary Outcome Measures
Name Time Method Secondary end point(s): - DAS28-high-sensitivity C-reactive protein (hsCRP): <br>- Proportion of patients achieving ACR20 response (baricitinib 2mg compared to placebo);Timepoint(s) of evaluation of this end point: - DAS28-high-sensitivity C-reactive protein (hsCRP): Change from baseline to Weeks 12 and 24<br>- Proportion of patients achieving ACR20 response (baricitinib 2mg compared to placebo) : Week 12